rHEALTH is developing a portable diagnostic platform designed to deliver lab-quality blood diagnostics from a single drop. The system combines multiplexed assays, miniaturized flow cytometry, and AI-driven interpretation, delivered via a handheld device and an accompanying app. The technology originated for space applications and is being adapted for consumer and point-of-care use. The products are in advanced stages of development and will require FDA approval prior to market.

One of the initial tests is the complete blood count. The platform enables rapid testing across biomarkers, small molecules, and nucleic acids, supporting decentralized diagnostics in settings such as pharmacies, urgent care centers, and homes. The technology was validated by NASA on the International Space Station, and the company positions the system alongside its vitals monitoring device and health AI.

rHEALTH has participated in on-orbit demonstrations and has received recognition, including finalist status in the Qualcomm Tricorder XPRIZE and a Nokia Sensing XCHALLENGE winner. The company holds 17 issued patents and has secured over $20 million in non-dilutive funding from NASA, NIH, and pharmaceutical partners, with about $3 million raised in equity capital. The team is led by Harvard/MIT-trained physician Eugene Chan and includes collaborations with NASA and NIH, with regulatory expertise in ISO 13485.

Market context indicates a large global diagnostics and monitoring opportunity, with a total addressable market reported at $323 billion (2023) and projected to exceed $400 billion by 2030; the serviceable addressable market is about $224 billion, with a serviceable obtainable segment focused on hematology and patient monitoring devices at roughly $16.2 billion.